ADM unveils its supportive solutions platform for users of GLP-1 and other anti-obesity medications (AOMs). The solutions platform leverages in-depth scientific research and market analysis and utilizes ADM’s ingredient resources and comprehensive product development capabilities and supports the growing need for personalized nutrition for consumers using or discontinuing AOMs.
